Besides other agenda items, two of the six Supervisory Board members of BRAIN AG are to be newly elected during the General Meeting. The terms of office of the Supervisory Board Chairman, Dr. Ludger Müller, and the Supervisory Board Member Christian Körfgen regularly end with the end of the upcoming General Meeting. Both are no longer available for a further term of office at their own request due to age or health reasons.
Two new Supervisory Board candidates are proposed for election to the Annual General Meeting. The two new candidates are Prof. Dr. Bernhard Hauer and Dr. Michael Majerus.
The candidate Prof. Dr. Bernhard Hauer is a molecular biologist. He has many years of research experience in the fields of biocatalysis and enzyme development. Since 2009 he is head of the Institute of Biochemistry and Technical Biochemistry at the University of Stuttgart. The candidate Dr. Michael Majerus is an economist and has held senior positions in several technology companies. He is Chief Financial Officer of SGL Carbon SE since July 2014.
In selecting these two candidates, the Supervisory Board has paid particular attention to continuity, experience and necessary expertise, with an additional focus on the indispensable industry, specialist and business knowledge of the candidates, which are essential for the exercise of the Supervisory Board mandates. The election proposals to the Annual General Meeting are consistent with the objectives adopted by the Supervisory Board regarding its composition.
The Members of the Supervisory Board and the entire Management Board of the Company wish to thank Dr. Ludger Müller and Christian Körfgen, who will leave the BRAIN Supervisory Board at the end of the Annual General Meeting on 7 March 2019, for the long-standing, successful and always trustworthy cooperation.
Further details on the Annual General Meeting as well as on the election proposals for the Supervisory Board are available on the website under www.brain-biotech.de/en/investor-relations/annual-general-meetings.
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN’s own products and active product components. Further information is available at www.brain-biotech.de/en.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.